Literature DB >> 28451942

The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study).

Patrizio Prati1, A Bignamini2, L Coppo3, A Naldi3, C Comi3, R Cantello3, G Gusmaroli4, U Walter5.   

Abstract

Transcranial sonography (TCS) shows an increased echogenic area of the substantia nigra (SN) in patients with Parkinson disease (PD). It has been increasingly used in the diagnosis of PD and its differentiation from atypical parkinsonian syndromes. Here, we studied the diagnostic accuracy of SN TCS in Italian patients. In this blinded cross-sectional study (NOBIS study), two expert neuro-sonologists performed TCS in 25 PD patients and 29 age- and sex-matched controls. The study participants were completely hidden to the TCS investigators using large drapery. One month later, the SN TCS recordings were re-read by the initial investigator, and cross-read by the second reader. Diagnostic accuracy was estimated on the first reading, intra-reader reliability on re-reading, and inter-reader reliability on cross-readings. The mean SN echogenic area was larger in the patients (0.24 cm2) than in the controls (0.15 cm2; Mann-Whitney test, p < 0.001). SN measures did not differ between right and left, or between ipsilateral and contralateral to the clinically more affected side. There was no correlation between SN echogenicity and PD severity or duration. High intra-reader (concordance correlation coefficient 0.93) and inter-reader (0.98) agreement of SN measurements was found. The diagnostic accuracy for the detection of PD was high (area under receiver-operating characteristic curve 0.91; 95% CI 0.83-1.00) with an optimum cut-off value for SN echogenic area of 0.18 cm2 with the device used here (specificity 0.83-0.90; sensitivity 0.72-0.92). This study supports the use of SN TCS in the diagnostic workup of PD if performed by trained readers.

Entities:  

Keywords:  Diagnostic accuracy; Parkinson disease; Reproducibility; Substantia Nigra; Transcranial sonography

Mesh:

Year:  2017        PMID: 28451942     DOI: 10.1007/s00702-017-1724-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  39 in total

1.  Predictive value of transcranial sonography in the diagnosis of Parkinson's disease.

Authors:  Jürgen Prestel; Katherine J Schweitzer; Anne Hofer; Thomas Gasser; Daniela Berg
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

2.  Brain parenchyma sonography detects preclinical parkinsonism.

Authors:  Uwe Walter; Christine Klein; Ruediger Hilker; Reiner Benecke; Peter P Pramstaller; Dirk Dressler
Journal:  Mov Disord       Date:  2004-12       Impact factor: 10.338

Review 3.  Transcranial sonography (TCS) of brain parenchyma in movement disorders: quality standards, diagnostic applications and novel technologies.

Authors:  U Walter; D Školoudík
Journal:  Ultraschall Med       Date:  2014-04-24       Impact factor: 6.548

4.  Transcranial sonography in the evaluation of Parkinson disease.

Authors:  Goran Kolevski; Igor Petrov; Vera Petrova
Journal:  J Ultrasound Med       Date:  2007-04       Impact factor: 2.153

5.  Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex.

Authors:  S Sastry; G W Arendash
Journal:  Neuroscience       Date:  1995-08       Impact factor: 3.590

6.  Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study.

Authors:  Philipp Mahlknecht; Klaus Seppi; Heike Stockner; Michael Nocker; Christoph Scherfler; Stefan Kiechl; Johann Willeit; Christoph Schmidauer; Arno Gasperi; Gregorio Rungger; Werner Poewe
Journal:  Neurodegener Dis       Date:  2013-05-18       Impact factor: 2.977

Review 7.  Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.

Authors:  Giovanni Rizzo; Massimiliano Copetti; Simona Arcuti; Davide Martino; Andrea Fontana; Giancarlo Logroscino
Journal:  Neurology       Date:  2016-01-13       Impact factor: 9.910

8.  The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study.

Authors:  Alexandra Gaenslen; Barbara Unmuth; Jana Godau; Inga Liepelt; Adriana Di Santo; Katherine Johanna Schweitzer; Thomas Gasser; Hans-Jürgen Machulla; Matthias Reimold; Kenneth Marek; Daniela Berg
Journal:  Lancet Neurol       Date:  2008-04-03       Impact factor: 44.182

Review 9.  Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis.

Authors:  Dun-Hui Li; Ya-Chao He; Jun Liu; Sheng-Di Chen
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

10.  The case for using the repeatability coefficient when calculating test-retest reliability.

Authors:  Sharmila Vaz; Torbjörn Falkmer; Anne Elizabeth Passmore; Richard Parsons; Pantelis Andreou
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more
  3 in total

1.  Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology.

Authors:  Daniel Richter; Aristeidis H Katsanos; Christoph Schroeder; Georgios Tsivgoulis; George P Paraskevas; Thomas Müller; Andrei V Alexandrov; Ralf Gold; Lars Tönges; Christos Krogias
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

Review 2.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

Review 3.  Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.

Authors:  Oxana P Trifonova; Dmitri L Maslov; Elena E Balashova; Guzel R Urazgildeeva; Denis A Abaimov; Ekaterina Yu Fedotova; Vsevolod V Poleschuk; Sergey N Illarioshkin; Petr G Lokhov
Journal:  Diagnostics (Basel)       Date:  2020-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.